UCSF UC San Francisco Previously Published Works

Title

Protocol for image-based small-molecule screen to identify neuroprotective compounds for dopaminergic neurons in zebrafish.

Permalink <https://escholarship.org/uc/item/40r6p946>

Journal STAR Protocols, 5(1)

Authors

Kim, Gha-Hyun Chen, Min Kwok, Sharie [et al.](https://escholarship.org/uc/item/40r6p946#author)

Publication Date

2024-01-12

DOI

10.1016/j.xpro.2024.102837

Peer reviewed

Protocol

Protocol for image-based small-molecule screen to identify neuroprotective compounds for dopaminergic neurons in zebrafish

Whole-organism-based screen holds promise for discovering biologically active compounds. However, high-content imaging is challenging due to the difficulty of positioning live animals and individual variability of neuron counts. Here, we present a protocol to identify neuroprotective compounds for dopaminergic neurons in zebrafish using an image-based small-molecule screen. We describe steps for raising larvae, agarose embedding, and treatment to induce neurodegeneration. We then detail procedures for live confocal imaging, image processing, and data analysis.

Publisher's note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.

Gha-hyun Jeffrey Kim, Min Chen, Sharie Kwok, Su Guo

happyiowa@gmail.com su.guo@ucsf.edu (S.G.)

Whole-organism in vivo imaging-based screening protocol neurodegenerative

Step-by-step guide to embed and position larvae dorsal down in 96-well plates

Live confocal imaging before and after treatment of zebrafish larvae diencephalon

Automated pipeline for quantifying dopamine neuron loss with open-source program

Kim et al., STAR Protocols 5, 102837 March 15, 2024 © 2024 The Authors. [https://doi.org/10.1016/](https://doi.org/10.1016/j.xpro.2024.102837) [j.xpro.2024.102837](https://doi.org/10.1016/j.xpro.2024.102837)

Protocol

Protocol for image-based small-molecule screen to identify neuroprotective compounds for dopaminergic neurons in zebrafish

Gha-hyun Jeffrey Kim,^{[1](#page-2-0)[,3,](#page-2-1)[*](#page-2-2)} Min Chen,¹ Sharie Kwok,^{1,[2](#page-2-3)} and Su Guo^{1[,2,](#page-2-3)[4](#page-2-4),*}

1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA 2School of Pharmacy, University of California, San Francisco, San Francisco, CA, USA

3Technical contact

4Lead contact

*Correspondence: happyiowa@gmail.com (G.-h.J.K.), su.guo@ucsf.edu (S.G.) <https://doi.org/10.1016/j.xpro.2024.102837>

SUMMARY

Whole-organism-based screen holds promise for discovering biologically active compounds. However, high-content imaging is challenging due to the difficulty of positioning live animals and individual variability of neuron counts. Here, we present a protocol to identify neuroprotective compounds for dopaminergic neurons in zebrafish using an image-based small-molecule screen. We describe steps for raising larvae, agarose embedding, and treatment to induce neurodegeneration. We then detail procedures for live confocal imaging, image processing, and data analysis.

For complete details on the use and execution of this protocol, please refer to Kim et al. $(2021).$ $(2021).$ $(2021).$ ¹

BEFORE YOU BEGIN

The protocol below describes an in vivo confocal imaging-based method to identify neuroprotective small molecules for dopaminergic neurons in larval zebrafish. Before starting the experiment, researchers should have the appropriate zebrafish with expression of the bacterial enzyme nitroreductase (NTR) fused with a fluorescent reporter (e.g., mCherry) driven by the tyrosine hydroxylase (th) promoter. The library selection and solubility of candidate compounds should also be reviewed by literature to ensure all control and test samples are treated with the same DMSO concentration.

Zebrafish husbandry and transgenic lines

Timing: 3 months

Here we will describe the selection and breeding of homozygous Tg[fuguth:gal4-uas:GFP; uas-NTRmCherry] lines that will be used for the assay. Having a sufficient batch of homozygous transgenic adult zebrafish expressing Tg[fuguth:gal4-uas:GFP; uas-NTRmCherry] is important as it allows for a consistent production of embryos and creating a weekly protocol for high throughput drug screening.

- 1. Generate homozygous Tg[fuguth:gal4-uas:GFP; uas-NTRmCherry] lines.
	- a. Cross two heterozygous Tg[fuguth:gal4-uas:GFP; uas-NTRmCherry] adult zebrafish to obtain embryos.
	- b. On day 4 or 5, screen larvae under a fluorescence stereo microscope with GFP and RFP.

A

Figure 1. Th-NTR-mCherry expression in larvae

(A) Example of a potentially homozygous larvae showing very bright fluorescence under the microscope as compared to (B) weak signals which are indicative of heterozygous lines. Sort the larvae that express very bright red fluorescence.

- i. To temporarily immobilize the larvae during screening, treat the larvae with tricaine at a low concentration (final concentration 160 µg/mL) 30 min prior to screening.
- ii. Sort the larvae that show strong fluorescence under RFP and label as ''potentially homozygous''.
- 2. Raise the potentially homozygous Tg[fuguth:gal4-uas:GFP; uas-NTRmCherry]
- 3. Identify homozygous lines.
	- a. Cross one potentially homozygous Tg[fuguth:gal4-uas:GFP; uas-NTRmCherry] larvae with AB WT.
	- b. Between 3 dpf and 5 dpf, screen larvae under the fluorescent RFP.
	- c. If all larvae express red TH neurons as shown in [Figure 1,](#page-3-0) the parent fish is considered to be homozygous and can be utilized as breeders for screening.
	- CRITICAL: To ensure proper rearing of zebrafish to adulthood with optimal light-dark cycles, feeding methods for different stages, and handling of fish tanks, refer to chapter 3 of The Zebrafish Book published by the ZFIN guidelines.^{[2](#page-14-1)}

Institutional permissions

The zebrafish is a vertebrate species. The study was reviewed and approved by the University of California, San Francisco Institutional Animal Care and Use Committee (approval number AN179000). The zebrafish system was regularly inspected by the University of California, San Francisco Laboratory Animal Resource Committee.

KEY RESOURCES TABLE

(Continued on next page)

Protocol

CRITICAL: Metronidazole in aqueous solution is sensitive to sunlight and UV radiation so ensure it is stored in a dry cool area with minimal light. When handling metronidazole, ensure fitting proper protective equipment including gloves and safety goggles. Conduritol B Epoxide is considered nonhazardous but the aqueous formulation should only be used within a day so always prepare a fresh aqueous batch for each experiment.

The reagents were obtained from the specified manufacturers in the key resources table but these can be substituted with any other manufacturer. However, it is important to ensure the exact reagents are being used. i.e., metronidazole has a molecular weight of 171.16 g/mol. There are other compounded products such as metronidazole benzoate which has different properties and may not be suitable for this assay.

The tricaine used as the anesthetic for embedding should not be substituted with other anesthetics such as isoflurane and lidocaine. For the 96 well plate, a flat bottom plate is highly recommended as other shapes such as the round bottom made larvae positioning more difficult and required more agarose volume.

MATERIALS AND EQUIPMENT

BEW can be stored between 20°C-25°C. Avoid using BEW that has been more than 2 weeks. Prepare fresh BEW if there is apparent algae growth or loss in the blue tint.

It is advised to aliquot the stock in 50 mL falcon tubes and store in -20°C. Avoid using MTZ stock if stored more than 6 months. Do a 5 fold dilution for the experiment to achieve a final concentration of 9 mM MTZ with 0.2% DMSO that is used for the 96 well screening plate.

The LMP agarose should be aliquoted into 2 mL Eppendorf tubes and maintained in the 50°C heat block. Always make fresh agarose for the weekly experiments.

Tricaine stock preparation: 4 mg/mL; weigh 400 mg tricaine and dissolve in 97.1 mL ddH₂O. Add 2.9 mL of 1 M Tris-HCl 9.0, to adjust the PH to ~7.5. For general use, dilute 1:25 to the working concentration of 160 µg/mL. For low dose tricaine treatment (e.g., 24 h incubation in agarose), dilute 1:100 to the working concentration of 40 μ g/mL.

CRITICAL: the LMP agarose and tricaine should be prepared exactly as described in the protocol. These concentrations were determined based on different experiments and were determined to be the best conditions to ensure the larvae are in stable conditions during imaging and the 24 hour incubation period.

PTU stock preparation: Weigh 0.3 g of PTU and add to 100 mL ddH₂O to make a suspension stock of 0.3%. Shake the bottle well prior to use. Dilute 1:100 to the working concentration of 0.003%.

CRITICAL: PTU can be harmful if swallowed, inhaled, or absorbed through the skin. It may cause respiratory and skin irritation. Always prepare stock solution with gloves in a wellventilated area.

STEP-BY-STEP METHOD DETAILS

Collect and raise transgenic embryos for screening

Timing: 5 days

This section describes the process of breeding zebrafish to produce sufficient larvae for 5 dpf and 6 dpf screening. The protocol is designed in a way that can be a routine screening assay that can be conducted on a weekly basis. By setting up zebrafish crosses midweek, while conducting the chemical treatment for the current batch, the experimenter(s) can be do subsequent compound screenings or validation studies without any gaps or delays.

1. In the late afternoon or early evening, set up homozygous Tg[fuguth:gal4-uas:GFP; uas-NTRmCherry] crosses with AB Wild Type, by putting one female and one male fish in a tank separated by a divider.

(optional) For obtaining a large number of eggs, pairing a female to male ratio of 2:1 during the crossing has shown to be safe and effective.

- 2. The next morning, pull the divider. Wait for 1–2 h. Collect embryos (Day 0) and transfer them to 30 mL of Blue Egg Water (2.4 g CaSO₄, 4 g IO Salt, 600 µL of 1% Methylene per 20 L) in a Petri dish.
- 3. Raise the larvae in an incubator with temperatures set at 28.5°C.
- 4. At 24 hpf (hours post fertilization), inspect the embryos and remove unfertilized eggs.
- 5. Treat the remaining larvae with 0.003% of 1-phenyl 2-thiourea and place back in the incubator.
- 6. On 4 dpf (days post fertilization), observe the mCherry⁺ TH neurons under the fluorescence stereo microscope RFP channel.
- 7. Transfer the mCherry⁺ larvae into a fresh BEW Petri dish and treat with PTU.
- 8. Place the larvae back into the incubator.

Note: Ensure standard light dark cycle of 14/10 h for crossing. When collecting embryos, ensure there are no more than 40 embryos per Petri dish with Blue Egg Water (BEW) during raising.

Agarose embedding in 96-well plate

Timing: 1–3 h per 96-well plate

The 96 well plate embedding is important as proper positioning of the larvae translates to higher image quality and analysis. Here we detailed the steps to ensure the best practice technique for proper embedding.

- 9. Prepare 1.2% low melting point (LMP) agarose in BEW. Make 2 mL aliquots in Eppendorf tubes and place them in a 50°C heat block.
- 10. For each agarose tube to be used for embedding, add 20 μ L of 4 mg/mL tricaine stock to each. Approximately 3 aliquot tubes are alternately used for a single 96 well plate.
- 11. Prepare 200 µL pipettes and cut the pipette tips to \sim 3 mm opening, enough to ensure the larvae can go through.
	- CRITICAL: the pipette tips should be cut in a manner that is just enough for the larvae to move without being damaged. Having too large of a diameter (cutting too high in the pipette) will not only make it difficult for pipetting, but also inaccurate volume.
- 12. Treat the Petri dish containing 5 dpf Tg[fuguth:gal4-uas:GFP; uas-NTRmCherry] larvae with 800 µL of tricaine stock. Wait 5 min.
- 13. Use the 200 µL micropipette and gently draw the anesthetized larvae by setting the micropipette to 40 μ L and transfer it to the agarose tube.

Note: Minimize the amount of BEW used during the transfer.

14. After submerging the larvae in the agarose tube, transfer the larvae from the agarose tube to the 96 well plate.

Note: Methods video S1 describes the flow of steps 5 and 6, from pipetting the anesthetized larvae, submerging the larvae in agarose, and transferring to 96 well plate.

15. Carefully position the larvae in a dorsal down position (for an inverted microscope) using forceps. Let the agarose solidify.

CRITICAL: embedding the larvae in the correct position is important because it can significantly affect the image quality. The goal is to position the larvae dorsally closest to the lens. In this protocol, since the confocal microscope is inverted, the larvae are embedded dorsal down.

Note: Sometimes positioning the larvae immediately after transferring to the 96 well plate can be difficult due to the viscosity of the agarose. Letting the larvae sit in the well for about 1 minute can allow for easier embedding. For best efficiency, transferring \sim 5 larvae at a time and embedding them can be a good way to minimize delays while giving enough time for the agarose to solidify. Methods video S2 describes the careful adjusting of the larvae position using the probes.

16. After embedding the larvae in the wells, add 100 µL BEW (no tricaine) to each well using a multichannel pipette. An example of the embedded larvae is shown in [Figure 2](#page-7-0).

Note: The 40 µL agarose was chosen based on a previous experiment performed to optimize the amount of agarose to BEW ratio when embedding. 40 µL was determined to be the optimal balance between ease of embedding while not harming or stressing larvae during the 24 h incubation period. As this volume is plate specific, it is advised to test different agarose volume.

Confocal imaging and compound treatment

Timing: 2 h for 2 consecutive days

The whole organism based phenotypic drug discovery method described in this protocol is a powerful method that focuses on the direct impact on neuronal integrity. The imaging consists of two sessions pretreatment and post treatment with compounds. By imaging the larvae twice, this significantly reduces the intravariability of DA neurons. This section describes the example plate design and detailed process of the imaging and chemical treatment.

17. Place the agarose embedded 96 well plate in the IN Cell Analyzer 6000 and close the lid.

- 18. Determine the configurations of the 96 well plate (thickness, material, brand, shape).
	- CRITICAL: What plate you use can significantly affect the quality of the image so it is important to ensure the same plate is used across a screening batch. The Greiner μ Clear

Figure 2. Embedding larvae in the 96-well plate

A single 5 dpf larvae is embedded per well with 40 µL of low melting point agarose. The zoomed in section shows each larvae is correctly positioned in the center of the well. The red square represents the estimated area that the 20x confocal lens field of view.

flat bottom plates were selected for our experiment as it provided a good surface area for embedding and image quality.

- 19. Use the 20x objective lens with the bright-field and DsRed fluorescence. Arrange the field of view toward the diencephalon region of the brain.
- 20. Observe a few wells and create a stack spanning \sim 100 μ m to cover the diencephalon region of the brain. Set each slice to $3 \mu m$. Set the capture mode as "max intensity" projection.

Note: This step is to create a stack of slices to ensure all 96 wells are covered.

21. For future use, save the settings within the .xaqp file. We have shared the .xaqp acquisition protocol in the GitHub repository <https://github.com/happyiowa/screening-protocol> [\(https://doi.](https://doi.org/10.5281/zenodo.10360186) [org/10.5281/zenodo.10360186\)](https://doi.org/10.5281/zenodo.10360186).

Note: The parameters used for the imaging protocol including the z-stack thickness and exposure will vary depending on what device is being used. We used the IN Cell Analyzer 6000 (RRID: SCR_015790) and the .xaqp file contains all the preset parameters used for this experiment. The experimenter should ensure the same parameter settings are used for all plates for consistency and to minimize batch effects.

- 22. After imaging, remove the plate from the IN Cell Analyzer.
	- a. Prepare a fresh batch of 45 mM MTZ in BEW (or 100 mM Conduritol B epoxide in 100% DMSO), and 10 mM of the screening compounds in 100% DMSO.
	- b. Calculate the volume needed to achieve the desired final concentrations.

Note: Our protocol is based on the following final concentrations: 9 mM MTZ, 500 μ M CBE, and 10μ M of the screening compound.

23. Treat the 96 wells with MTZ (or CBE), and the screening compounds based on the plate setup.

Note: To ensure adequate sample size, it is recommended to use one condition for each row (n = 12). Sample plate conditions are as follows: Top row positive control (0.2% DMSO), bottom row negative control (9 mM MTZ or 500 μ M CBE), and the screening compounds + MTZ or CBE in between. An example of the plate setup is shown in [Figure 3.](#page-8-0) The optional light box can be useful during this step to clearly visualize the chemical treatment. Place the lightbox under the 96 well plate and inspect for any chemical impurities or misplaced larvae.

Figure 3. Example 96 well plate setup

Each row represents as a single condition (n = 12). The top and bottom row are considered positive (0.2% DMSO), and negative control (MTZ or CBE) with screening compounds + MTZ/CBE in the middle rows.

Image analysis

Timing: 5 h

The large dataset of confocal images obtained are analyzed with the CellProfiler image analysis software. The software automatically identifies the DA neurons by using the bright-field images of the larvae brain and quantifies the intensity. All information on the custom pipeline are shared in the repository.

- 24. The video explaining the detailed analysis pipeline can be found in the GitHub repository <https://github.com/happyiowa/screening-protocol>.
- 25. The open source CellProfiler image analysis software by the Broad Institute was used for analyzing the diencephalon DA neurons of zebrafish.
- 26. Download the latest CellProfiler for MacOS or Windows in <https://cellprofiler.org/releases>. The version used for this analysis was on version 4.2.
- 27. The image files or folders of the images can be uploaded directly to CellProfiler in the ''images'' tab.
- 28. Go to the ''NamesAndTypes'' section and click ''update'' to assign all images with the corresponding image type, fluorescence, and designated name.

Note: If there is a mismatch in the rules or names assigned, the images will not be updated. Fix any matching rules if this occurs as this step is required to proceed with the pipeline.

- 29. Click on the ''Smooth'' function tab. The bright field images are used as a mask to locate the approximate position of the diencephalon.Select the bright-field images as the input.
- 30. Use the ''Gaussian Filter'' to blur and obscure features smaller than the specified diameter.
- 31. Next, proceed to the ''ImageMath'' tool to invert the 8-bit fluorescence image and propagate the image to identify DA neurons. Apply a 1.0 multiplication operation for the image inversion.
- 32. After the bright-field images have been smoothed and inverted, move to the ''MaskImage'' tab to overlay the bright-field images with the fluorescent RFP images.
- 33. Proceed to the ''IdentifyPrimaryObject'' section. This is the most important section as it is the step that identifies the DA neurons based on the assigned parameters.

Note: The intensity threshold determines whether each pixel will be considered foreground or background. There are four automatic detection algorithms (otsu, minimum cross entropy, robust background, and measurement) or the parameters can also be set manually. In our pipeline we introduced the manual model but make sure to try different parameters in ''test mode'' as some threshold strategies may work better with your experiment. The CellProfiler manual also has detailed explanations for each automatic algorithm [https://](https://cellprofiler-manual.s3.amazonaws.com/CellProfiler-4.2.6/index.html) [cellprofiler-manual.s3.amazonaws.com/CellProfiler-4.2.6/index.html.](https://cellprofiler-manual.s3.amazonaws.com/CellProfiler-4.2.6/index.html)

34. Proceed to the ''MeasureObjectIntensity'' tab to quantify the fluorescent intensity of DA neurons. Export the quantified intensity values using the ''ExportToSpreadsheet'' command and save the colorized neurons to ensure that correct neuron diameter reference ranges are set.

Note: The example of image outputs and the corresponding quantification of object identified outputs are shown in [Figure 4.](#page-10-0)

35. For each 96 well plate analysis, normalize the DA neuron intensity to the positive control and do a student-t test between the positive and negative control.

Note: A video going through the statistical analysis of the spreadsheet output can be found in the data repository <https://github.com/happyiowa/screening-protocol>.

A

Figure 4. DA neuron isolation and fluorescence intensity analysis

Example steps in the CellProfiler pipeline that highlights the identification of TH neurons based on the pixel size. (A) Using the 20x bright field image to overlay the fluorescent image to automatically detect the eyes for removal of autofluorescence.

(B) The ''IdentifyPrimaryObjects'' command with the global threshold strategy configurations correctly capture the neurons that are later used to quantify intensity.

EXPECTED OUTCOMES

This protocol was designed as a routine candidate compound screening method spanning the duration of 1 week. This allows for proper planning of experiments, raising larvae, and conducting analysis routinely to scan a large library of compounds in vivo for hit identification. If the exact concentrations of MTZ or CBE are used, and the 24 h incubation time is carried out as listed in the protocol, the expected DA neuron intensity loss during the 5 dpf to 6 dpf incubation period should be \sim 65% in the negative control. Higher concentrations can result in more significant ablation and can be suitable for some studies. The dose response and rationale for the MTZ or CBE concentration and treatment duration can be found in our previous work.⁴ If there is indeed a candidate compound, the pre-treatment to post-treatment DA neuron intensity will result in a value in between the positive control (0.2% DMSO) and negative control (MTZ or CBE treatment). With a sample size of n = 10 to 12 depending on the successful embedding and imaging, this will be sufficient to conduct a student's t-test between the negative control and the candidate neuroprotective compound-treated group to determine significance.

QUANTIFICATION AND STATISTICAL ANALYSIS

After running the CellProfiler pipeline for image analysis, the ''ExportToSpreadsheet'' command will output the .xlsx file as shown in the example [Table 1.](#page-11-0) The "Intensity_TotalIntensity" is the variable that reflects the total fluorescence of the isolated DA neurons. The ratio between the post-treatment and pre-treatment is used to indicate the relative DA neuron intensity. To remove batch effects and minimize variability across different experimental time points, a normalization process is done using the positive control as shown in [Table 2.](#page-11-1) The positive untreated control is set to an average of 1 and the coefficient is used to normalize across all treatment groups including the negative control. The final example figure for a single plate experiment is shown in [Figure 5.](#page-12-0)

LIMITATIONS

The screening assay is based on the 5 to 6 dpf larvae which is not representative of the time point of neurodegeneration given that neurodegenerative diseases occur in later stages of life for humans.^{[5](#page-14-4)} Also, the chemical ablation method with CBE or MTZ do not recapitulate the exact etiology or pro-gression of Parkinson's Disease (PD).^{[6,](#page-14-5)[7](#page-14-6)} However, our previous work has shown that the NTR-MTZ model and CBE model have mechanistic relevance to PD in the context of mitochondrial dysfunc-tion.^{[1](#page-14-0)} Also, the CBE treatment has been widely used to induce Gaucher's disease, an autosomal recessive disorder highly linked to PD.^{[8](#page-14-7)[,9](#page-14-8)}

The protocol utilizes a 20x objective lens, which requires precise positioning of the larvae. There are lower magnification lenses such as 4x or 10x objectives which can be more forgiving and capture a larger area of the well, but it will also come with the compromise of lower resolution when doing the data analysis.

As the neuron image analysis with CellProfiler and ImageJ is based on the size of the neuron and intensity, it is prone to capture neurons or particles that are not DA neurons. Upon MTZ and CBE treatment, it is possible that fluorescent puncta remain. Without further validation, our assay is limited on whether those damaged neurons remain functional. It is important to correctly use the sizing tool to ensure those debris are not falsely captured during the quantification.

TROUBLESHOOTING

Problem 1

Hard to position larvae in the dorsal down position in the 96-well plates (related to step 7 in the [agarose embedding in 96 well plate](#page-6-0) section) .

Potential solution

- Try not to position the larvae immediately after placing it in the well. Allowing time for agarose to be slightly solidified helps.
- Make sure to accurately measure out the agarose needed. If 1.2% is difficult, you can also try increasing it slightly more up to 1.5%. However, agarose concentrations beyond 1.5% has shown to be stressful for larvae during the 24-h incubation period.
- The general field of view for each objective lens is depicted in [Figure 6](#page-12-1). To assist with accurate positioning, create a template that clearly indicates the center of the well and use that as a marker to align all embryos in the general position.

Problem 2

Identifying DA neurons incorrectly in the image analysis software (referring to step 10 in the image analysis methods).

Figure 5. Bar graph visualization of the screening plate analysis

A t-test between the positive control (blue) and negative control (red) shows significant DA neuron ablation. The difference between the negative control and the different treatment groups (Drug A, B, and C) should be assessed to determine the significance of a hit candidate.

Potential solution

 The size of the DA neurons in the diencephalon region can be slightly different for each imaging session. This could result in the CellProfiler not being able to capture the correct neurons, either overcounting or undercounting which can result in inaccurate quantification.

Figure 6. Template for 96-well plate positioning

To assist with the proper alignment and embedding of the dorsal down positioning of the larvae, a custom created template is printed and placed in the bottom of the plate. The red, green, and blue squares represent 20x, 10x and 4x imaging area that the IN Cell 6000 Analyzer can cover. The template is available in the repository (Specific for the Greiner µClear plates).

 For each plate analyzed by the CellProfiler software, do a test run on a few positive control samples, adjusting the particle radius ''IdentifyPrimaryObjects''.

Problem 3

No significant DA neuron damage in negative control.

Potential solution

- The MTZ and CBE should ideally be prepared fresh for each screening as it is important to ensure that there is a significant difference between the positive and negative control. The 9 mM MTZ was chosen based on the consistent ablation of approximately 50% of the DA neurons.
- Do not reuse leftover MTZ stock solution after performing a batch of plates.

Problem 4

Out of focus images (referring to step 3 of the Confocal Imaging and compound treatment methods).

Potential solution

 Every embedded plate will have slightly different focus and z-stack. Always make sure to observe several example plates before automating the capture. Since the ''max intensity'' projection is used, it is okay to have a slightly thicker stack of up to \sim 150 μ m to ensure all diencephalon regions are captured across the plates.

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Su Guo ([su.guo@ucsf.edu\)](mailto:su.guo@ucsf.edu).

Technical contact

Technical questions on executing this protocol should be directed to and will be answered by the technical contact, Gha-hyun Jeffrey Kim ([happyiowa@gmail.com\)](mailto:happyiowa@gmail.com).

Materials availability

This study did not generate new unique reagents.

Data and code availability

The IN Cell Analyzer acquisition protocols and custom generated pipelines for DA neuron analysis are all available in [https://github.com/happyiowa/screening-protocol.](https://github.com/happyiowa/screening-protocol)

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.xpro.2024.102837>.

ACKNOWLEDGMENTS

We thank Michael Munchua and Vivian Yuan for excellent animal care. The IN Cell analyzer 6000 equipment was provided by the UCSF Sandler Neurosciences Center. This project was funded by NIH R21 NS082938, R01 NS120219, and DoD CDMRP PD170068 (to S.G.); the UCSF Mary Anne Koda-Kimble Seed Award for Innovation; and the Luis Zeh Fellowship (to G.J.K.).

AUTHOR CONTRIBUTIONS

Conceptualization and methodology, G.J.K. and S.G.; validation, M.C., S.K., G.J.K., and S.G.; analysis, G.J.K.; writing, M.C., S.K., G.J.K., and S.G.; resources, S.G.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

- 1. [Kim, G.-H.J., Mo, H., Liu, H., Wu, Z., Chen, S.,](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref1) [Zheng, J., Zhao, X., Nucum, D., Shortland, J.,](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref1) [Peng, L., et al. \(2021\). A zebrafish screen reveals](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref1) [Renin-angiotensin system inhibitors as](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref1) [neuroprotective via mitochondrial restoration in](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref1) [dopamine neurons. Elife](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref1) 10, e69795.
- 2. [Westerfield, M. \(2007\). THE ZEBRAFISH](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref2) [BOOK:A Guide for the Laboratory Use of](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref2) [Zebrafish Danio* \(Brachydanio\) Rerio, 4th ed.](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref2) [\(University of Oregon\).](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref2)
- 3. [Stirling, D.R., Swain-Bowden, M.J., Lucas, A.M.,](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref3) [Carpenter, A.E., Cimini, B.A., and Goodman, A.](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref3) [\(2021\). CellProfiler 4: improvements in speed,](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref3) [utility and usability. BMC Bioinf.](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref3) 22, 433.
- 4. [Kim, G.H.J., Mo, H., Liu, H., Okorie, M., Chen, S.,](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref4) [Zheng, J., Li, H., Arkin, M., Huang, B., and Guo,](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref4) [S. \(2022\). In Vivo Dopamine Neuron Imaging-](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref4)[Based Small Molecule Screen Identifies Novel](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref4) [Neuroprotective Compounds and Targets.](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref4) [Front. Pharmacol.](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref4) 13, 837756.
- 5. [Armstrong, M.J., and Okun, M.S. \(2020\).](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref5) [Diagnosis and Treatment of Parkinson Disease:](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref5) [A Review. JAMA](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref5) 323, 548–560.
- 6. [Haddad, F., Sawalha, M., Khawaja, Y.,](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref6) [Najjar, A., and Karaman, R. \(2017\).](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref6) [Dopamine and Levodopa Prodrugs for the](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref6) [Treatment of Parkinson's Disease. Molecules](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref6) 23[, 40.](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref6)
- 7. [Exner, N., Lutz, A.K., Haass, C., and Winklhofer,](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref7) [K.F. \(2012\). Mitochondrial dysfunction in](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref7) [Parkinson](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref7)'[s disease: Molecular mechanisms and](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref7) [pathophysiological consequences. EMBO J.](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref7) 31, [3038–3062.](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref7)
- 8. [Riboldi, G.M., and Di Fonzo, A.B. \(2019\). GBA,](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref8) [Gaucher Disease, and Parkinson's Disease:](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref8) [From Genetic to Clinic to New Therapeutic](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref8) [Approaches. Cells](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref8) 8, 364.
- 9. [Niederkofler, V., Auer, E., Amschl, D., Neddens,](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref9) [J., and Hutter-Paier, B. \(2019\). CBE treatment of](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref9) [alpha-synuclein over-expressing and wildtype](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref9) [mice models Gaucher disease pathology. Mol.](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref9) [Genet. Metabol.](http://refhub.elsevier.com/S2666-1667(24)00002-9/sref9) 126, S108–S109.